Drug intelligence / Profile preview

PRX-402

Development stage: Unknown
Lead developer: Prazer Therapeutics
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

PRX-402 is a proteolysis-targeting chimera (PROTAC) drug candidate that was initially developed by Praser Therapeutics. It was designed for the treatment of central nervous system diseases, targeting disorders within the nervous system. As a PROTAC, its mechanism involves inducing targeted protein degradation via the ubiquitin-proteasome pathway, although specific molecular targets have not been disclosed publicly. The drug reached discovery phase but has since been discontinued in development[1].

Beyond the preview

Go deeper on PRX-402.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRX-402.

Explore the full profile